Inclusion Criteria:
Thirty six healty pregnant women who had COVID-19 infection with mild to moderate symptoms according to The National Institutes of Health (NIH) classification in the second trimester of pregnancy were included in the patient group (COVID group)[10,11]. Infection was confirmed with a reverse transcription-polymerase chain reaction (RT-PCR) test with nasopharyngeal swab in all patients and none of them hospitalized. Six weeks after recovery, fetal echocardiogram performed. During the same period, thirty gestational and maternal age-matched unvaccinated pregnant women monitored for routine prenatal care who had no history or symptoms of COVID-19 infection included in control group (CONTROL group). Pregnant women with chronic systemic diseases (diabetes mellitus, hypertension, chronic renal failure), gestational diabetes, smokers, and those with fetal anomalies, fetal growth restriction, multifetal pregnancy were excluded the study. On the postnatal period, pregnancies complicated by preterm delivery before 37th week and neonatal intensive care unit admission (NICU) were not included. The patients’ descriptive data were recorded. Seven participants were excluded from the study due to preterm birth (One delivered at 33th, four delivered at 35th, 2 delivered at 36th GW), 3 participants were excluded from the study due to the NICU admission for respiratory distress although they were term born. The participants who met the study criteria but did not continue postnatal follow-up excluded from study data (8 patients and 5 controls). The first postnatal echo was performed within the first two weeks, after 4thday of life for ductus closure. The follow-up (second) echo was performed at 6-8 weeks of life for the pulmonary pressure to return to normal.